-
Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba
Oncoscience | April 7th, 2016
At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...
-
Innokeys Pte. Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
Oncoscience | July 22nd, 2015
The acquisition enables Innokeys to fully lead clinical and commercial development of Nimotuzumab in Europe. Transactio...
-
Oncoscience AG and GenIlac agree on cooperation terms in Turkey
Oncoscience | July 7th, 2010
Oncoscience, Wedel and GenIlac, Ankara agree on cooperation in Turkey for Nimotuzumab(Theraloc®), an EGFr antibody, whi...
-
Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009
Oncoscience | October 9th, 2009
On Friday October 9th, 2009 results from the Phase III study of the monoclonal antibody Nimotuzumab were presented. At ...
-
Funcrypta – Poster presentation at European Bioperspectives
Oncoscience | October 4th, 2008
Oncoscience AG is a member of the German Funcrypta project. Within the scope of this cooperation a poster will be presen...